RESEARCH
www.commprac.com
ISSN 1462 2815

ADVANCEMENTS IN UNDERSTANDING AND MANAGING TINEA CAPITIS: A COMPREHENSIVE REVIEW FOR PHARMACISTS

Aminat Sarauniya Omar [1], Salem Sanusi Lawan [2], Evans Miahengate Auqustino [3], Dr. Bhavana Singh [4]*, Amrish Chandra [5], Vandana [6] and Hema Arya [7]

[1,2,3,5,6,7] School of Pharmacy, Sharda University, Plot no 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh.
[4] Assistant Professor, School of Pharmacy, Sharda University, Plot no 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh.
*Corresponding Author Email: bhavanasingh53@gmail.com

DOI: 10.5281/zenodo.13780330

Abstract

Tinea capitis, a common fungal infection primarily affecting children, presents challenges in diagnosis and management. This review provides a comprehensive overview of tinea capitis, including epidemiology, etiology, clinical manifestations, diagnostic approaches, treatment options, and prevention strategies. Epidemiological studies highlight the increasing incidence of tinea capitis worldwide, with varying prevalence rates across different regions and populations. The etiology involves dermatophyte fungi, primarily Trichophyton species, transmitted through direct contact with infected individuals or contaminated objects. Clinical manifestations range from inflammatory to non-inflammatory types, with diverse presentations and potential complications. Diagnostic approaches encompass direct microscopy, fungal culture, molecular techniques, Wood's lamp examination, and distinguishing features from other scalp conditions. Treatment modalities include systemic and topical antifungal agents, with considerations for special populations and adjunctive therapies. Prevention strategies emphasize personal hygiene practices, environmental measures, and education campaigns to mitigate transmission and reduce the burden of tinea capitis. Emerging research focuses on novel therapeutic approaches, including nanotechnology-based antifungals and host-targeted therapies. Overall, this review highlights the importance of early recognition, accurate diagnosis, and tailored management strategies in addressing tinea capitis effectively.

Keywords: Tinea Capitis, Dermatophytosis, Fungal Infection, Children, Scalp Infection.

1. INTRODUCTION

Tinea capitis, or scalp ringworm, is a common fungal infection affecting both children and adults, posing significant public health concerns due to its contagious nature and associated morbidity. Despite medical advancements, it remains a challenge, especially in regions with limited resources and poor sanitation [1]. Epidemiologically, it varies by age, gender, socio-economic status, and geography, with urban areas experiencing higher prevalence due to overcrowding and inadequate hygiene. Understanding its causes, primarily dermatophytes like Trichophyton and Microsporum, and modes of transmission through direct contact or contaminated items, is crucial for management and control [2]. Clinically, it presents with mild to severe symptoms, requiring thorough evaluation for accurate diagnosis. Treatment involves systemic antifungals like griseofulvin and terbinafine, supplemented by topical agents, but challenges like adherence and resistance exist. Preventive measures, including promoting personal hygiene and environmental disinfection, are vital in controlling spread [3]. Comprehensive reviews are needed to address gaps in understanding and propose evidence-based strategies for healthcare practitioners and policymakers. Ultimately, enhancing understanding and interventions can reduce the burden of tinea capitis and improve global health outcomes[4].

2. EPIDEMIOLOGY OF TINEA CAPITIS

Tinea capitis, a common fungal infection of the scalp primarily affecting children, represents a significant public health concern globally. Understanding its epidemiology, including prevalence rates, demographic patterns, and geographic variations, is essential for effective disease control and management[5].

2.1 Prevalence

The prevalence of tinea capitis varies widely across different regions and populations, influenced by factors such as socio-economic status, hygiene practices, climate, and access to healthcare. While accurate prevalence data are often challenging to obtain due to underreporting and variability in diagnostic practices, several studies have provided insights into the burden of disease[6].

In North America and Europe, prevalence rates of tinea capitis have been reported to range from 0.1% to 12%, with higher rates observed in urban, densely populated areas and among socioeconomically disadvantaged populations [7]. For instance, studies conducted in urban centers such as New York City and London have reported prevalence rates exceeding 10% in certain communities[8].

In Africa, Asia, and Latin America, where overcrowded living conditions and limited access to healthcare are more prevalent, tinea capitis is considered endemic, with reported prevalence rates ranging from 20% to 50% or higher in some regions. For example, studies conducted in Nigeria, India, and Brazil have documented high prevalence rates of tinea capitis among school-aged children, particularly in rural areas[9].

The age distribution of tinea capitis cases also varies, with the highest incidence observed in children aged 3 to 7 years. However, cases can occur in individuals of all ages, including adults and the elderly. Gender differences in prevalence rates are less pronounced, although some studies have suggested a slightly higher prevalence among boys compared to girls[10].

Furthermore, certain demographic factors, such as race and ethnicity, may influence susceptibility to tinea capitis. For example, studies have reported higher prevalence rates among individuals of African descent, possibly due to genetic predisposition or cultural practices[11].

2.2 Demographic Patterns and Geographic Variations

Demographic patterns in the epidemiology of tinea capitis reflect underlying socio-economic disparities and environmental factors. Urban areas with poor sanitation, overcrowded housing, and limited access to healthcare services are at higher risk of tinea capitis outbreaks[12]. Additionally, factors such as climate and environmental conditions, including humidity and temperature, may contribute to the geographical distribution of tinea capitis[13]. Geographically, tinea capitis is more prevalent in tropical and subtropical regions, where environmental conditions favor the growth and transmission of dermatophytes [14]. However, cases have been reported in temperate climates as well, indicating the adaptability of the causative fungi to diverse environments [15]. In conclusion, tinea capitis represents a significant public health concern with varying prevalence rates across different regions and populations. Understanding the epidemiology of tinea capitis, including demographic patterns and

geographic variations, is crucial for implementing targeted prevention and control measures to reduce the burden of disease [16].

3. ETIOLOGY AND PATHOGENESIS

3.1 Causative Agents

Dermatophytes are the primary causative agents of tinea capitis, with Trichophyton species being the most commonly implicated. Among Trichophyton species, Trichophyton tonsurans is frequently associated with tinea capitis in urban settings, particularly in North America and Europe[17]. Microsporum species, such as Microsporum canis and Microsporum audouinii, are also known to cause tinea capitis, with M. canis being prevalent in regions with high rates of animal-to-human transmission. The choice of causative agent may vary geographically and temporally, influenced by factors such as population demographics, socio-economic conditions, and environmental factors. Emerging pathogens and changes in epidemiological patterns underscore the dynamic nature of tinea capitis etiology[18].

3.2 Mode of Transmission

Tinea capitis is primarily transmitted through direct contact with infected individuals or contaminated fomites. Modes of transmission may include sharing of personal items such as combs, brushes, hats, and bedding, as well as close contact with infected animals, particularly household pets such as cats and dogs[19]. In addition to direct transmission, environmental sources such as contaminated surfaces, soil, and hair grooming implements may serve as reservoirs for dermatophyte spores, facilitating the spread of infection within households, schools, daycare centers, and other communal settings. The mode of transmission may also vary depending on the causative agent. For instance, M. canis, a zoophilic dermatophyte commonly found in cats and dogs, can be transmitted from infected animals to humans, leading to zoonotic transmission[20].

4. CLINICAL MANIFESTATIONS

Tinea capitis, a fungal infection of the scalp caused by dermatophytes, presents with a spectrum of clinical manifestations, ranging from mild scaling to severe inflammatory lesions. Understanding the diverse clinical phenotypes is essential for accurate diagnosis and appropriate management[21].

4.1 Inflammatory Types

Inflammatory types of tinea capitis are characterized by pronounced inflammation, erythema, and often, suppuration. The most severe form of inflammatory tinea capitis is known as kerion, which presents as boggy, tender nodules with surrounding erythema and pustules[22]. Kerion is a manifestation of an exaggerated immune response to the fungal infection and may be associated with regional lymphadenopathy[23]. Other inflammatory presentations include folliculitis, characterized by papules and pustules around the hair follicles, and abscess formation. Inflammatory tinea capitis may also present with diffuse erythema, scaling, and crusting of the scalp, mimicking other inflammatory dermatoses such as seborrheic dermatitis or psoriasis[24].



Figure 1: Types of Tinea capitis

4.2 Non – Inflammatory Types

Non-inflammatory types of tinea capitis are typically milder in presentation and may manifest as dry scaling, fine white or grayish scales, and localized areas of alopecia as shown in figure 1[25]. Non-inflammatory tinea capitis may be asymptomatic or associated with mild pruritus.

Common non-inflammatory presentations include scaling patches or plaques with broken-off hairs, known as "black dot" tinea capitis, and diffuse scaling without significant inflammation[26].

Non-inflammatory tinea capitis may also present as a chronic, indolent infection with minimal symptoms, making diagnosis challenging without a high index of suspicion. The absence of pronounced inflammation may lead to misdiagnosis or delayed treatment initiation, particularly in cases with atypical clinical features[27].

5. DIAGNOSTIC APPROACHES

Accurate diagnosis of tinea capitis relies on a combination of clinical assessment, laboratory tests, and adjunctive tools to confirm the presence of fungal infection and identify the causative organism. A systematic approach to diagnostic evaluation is essential for guiding appropriate management and preventing misdiagnosis[28].

5.1 Clinical Examination

Clinical examination plays a central role in the diagnosis of tinea capitis, with characteristic findings aiding in differential diagnosis. Key features include scaling, erythema, alopecia, and inflammation of the scalp, often with patchy involvement and broken-off hairs ("black dots").

Inflammatory types may present with boggy nodules, pustules, and regional lymphadenopathy, while non-inflammatory types may exhibit mild scaling without significant inflammation[29].

Wood's lamp examination, utilizing ultraviolet light, may aid in the detection of certain fungal species, such as Microsporum canis, which fluoresces green. However, this method has limited sensitivity and specificity and should be used in conjunction with other diagnostic modalities[30].

5.2 Laboratory Tests

Laboratory tests are essential for confirming the diagnosis of tinea capitis and identifying the causative organism. Direct microscopy of scalp scrapings or plucked hairs allows for the visualization of fungal elements, such as hyphae, arthroconidia, or spores. Calcofluor white or potassium hydroxide (KOH) preparations may enhance the visualization of fungal elements under microscopy[31].

Culturing of scalp specimens on fungal media, such as Sabouraud agar, allows for the isolation and identification of dermatophyte species. Cultures should be incubated at room temperature for up to four weeks to maximize fungal growth.

Identification of the causative organism based on colony morphology, microscopic examination, and biochemical tests is essential for guiding targeted antifungal therapy[32].

5.2.1 Direct Microscopy

Direct microscopy, also known as microscopic examination or microscopy with potassium hydroxide (KOH) preparation, is essential for diagnosing tinea capitis. Gently scrape the affected scalp area with a scalpel blade, curette, or glass slide edge. Alternatively, plucked hairs with roots intact can be collected[33].

Transfer the sample to a glass slide and add a few drops of 10-20% KOH solution. Cover with a coverslip and let it stand to dissolve keratin debris and reveal fungal elements. View the KOH mount under a light microscope using low and high-power objectives (typically 10x and 40x magnification).

Look for characteristic fungal structures like septate hyphae, branching hyphae, and spores. These appear as translucent structures against keratin debris. Positive findings show fungal elements consistent with dermatophyte infection, such as septate hyphae and spores. Negative results mean no fungal elements were found or the sample quality was inadequate[34].

5.2.2 Fungal Culture

Fungal culture is a crucial diagnostic method for confirming dermatophyte fungi in suspected cases of tinea capitis. The procedure involves aseptically collecting a scalp sample and inoculating it onto suitable fungal culture media[35]. Incubation at optimal temperatures allows fungal growth, typically visible within 1-2 weeks.

Colonies are then examined for characteristic morphology, and representative ones are further identified through microscopic examination. Dermatophyte growth is confirmed based on observed morphological features. This method aids in accurately identifying the causative organism, essential for effective management of tinea capitis[36].

5.2.3 Molecular Techniques

Molecular techniques, notably Polymerase Chain Reaction (PCR), offer highly sensitive and specific means for detecting fungal DNA in suspected cases of tinea capitis. PCR involves amplifying specific regions of the fungal genome, like the internal transcribed spacer (ITS) region, using sequence-specific primers and DNA polymerase enzyme[37].

Here's a simplified overview of the PCR procedure firstly the fungal DNA is extracted from clinical specimens, typically obtained from scalp scrapings or plucked hairs, using commercial kits or manual methods. Specific PCR primers targeting conserved regions of the fungal genome, such as the ITS region, are designed. These primers are specific to dermatophyte species. The extracted fungal DNA serves as the template for PCR amplification.

The PCR reaction mixture contains DNA primers, DNA polymerase enzyme, nucleotides, and buffers[38]. The PCR reaction mixture undergoes a series of thermal cycles, including denaturation, annealing, and extension, leading to the exponential amplification of target DNA sequences. Amplified PCR products are detected using techniques like gel electrophoresis or real-time PCR.

Gel electrophoresis visualizes PCR products based on size, while real-time PCR allows quantitative measurement of DNA amplification in real-time. PCR results are analyzed to determine the presence of dermatophyte DNA and identify the species based on the size and sequence of amplified PCR products. Positive results indicate tinea capitis presence, while negative results suggest absence of fungal DNA or inadequate sample quality[39].

5.3 Wood's Lamp Examination

Wood's lamp examination, also known as UV light examination, is a valuable tool for diagnosing tinea capitis, especially caused by certain dermatophyte species that fluoresce under UV light. This non-invasive technique helps detect scalp fungal infections by highlighting characteristic fluorescence patterns associated with dermatophyte fungi[40].

Wood's lamp emits long-wave ultraviolet (UV-A) light (320-400 nm), causing substances like porphyrins produced by dermatophyte fungi to fluoresce. Dermatophyte fungi, like Microsporum canis, emit a green fluorescence when exposed to UV light, aiding in scalp fungal element visualization. Dim ambient light in the examination room and remove any head coverings or hair products hindering examination[41].

Position the lamp 4-6 inches from the scalp, directing UV light onto affected areas, systematically examining the entire scalp surface for fluorescence. Look for characteristic green fluorescence, indicating dermatophyte infection, and compare with surrounding skin for intensity differences. Record findings, including fluorescence location and distribution, and associated clinical features for future reference using clinical photography or written descriptions[42].

6. TREATMENT AND MODALITIES

6.1 Systemic Antifungal Agents:

Table 1: Comparison of Antifungal Agents for Dermatophyte Infections: Mechanisms of Action, Administration, and Treatment Duration

Antifungal Agent	Mechanism of Action	Administration	Treatment Duration
Griseofulvin	Inhibits fungal cell division and proliferation, leading to arrest of growth and eradication of infection[1].	Oral tablet or liquid suspension, dosed based on weight and severity of infection[28].	Typically 6 to 12 weeks, depending on species and response to therapy[8].
Terbinafine	Inhibits fungal cell wall synthesis, leading to disruption of growth and eventual fungal death[10].	Oral tablet, dosed based on weight and severity of infection[4].	Generally 4 to 6 weeks.
Fluconazole	Inhibits fungal cell membrane synthesis, leading to disruption of growth and eventual fungal death[2].	Oral tablet or liquid suspension, dosed based on weight and severity of infection[2].	Generally 2 to 4 weeks.

7.2 Topical Antifungal Preparations

Table 2: Comparison of various Topical Antifungal prepration

Clotrimazole	Ciclopirox	Selenium Sulfide
Clotrimazole is a broad-spectrum antifungal agent that is commonly used in topical formulations for the treatment of tinea capitis[2].	Ciclopirox is a broad-spectrum antifungal agent with activity against dermatophyte fungi and other fungal pathogens[3].	Selenium sulfide is an antifungal agent with activity against dermatophyte fungi and other fungal pathogens[3].
It works by inhibiting fungal cell membrane synthesis, leading to the disruption of fungal growth and eventual fungal death[2].	Ciclopirox is available in topical formulations such as creams, lotions, and shampoos, which can be applied directly to the affected scalp area[3].	It works by inhibiting fungal growth and reducing the shedding of skin cells, helping to alleviate symptoms such as scaling and inflammation associated with tinea capitis[3].
Clotrimazole is available in various formulations, including creams, lotions, and shampoos, which can be applied directly to the affected scalp area[7].	Topical ciclopirox is typically applied once or twice daily to clean, dry scalp skin, with treatment duration ranging from several weeks to months depending on the severity of the infection[3].	Selenium sulfide is available in topical formulations such as shampoos, which can be applied directly to the affected scalp area[3].
Topical clotrimazole is typically applied once or twice daily to clean, dry scalp skin, with treatment duration ranging from several weeks to months depending on the severity of the infection[7].		Topical selenium sulfide shampoo is typically applied once daily to wet hair and scalp, lathered and left on for several minutes before rinsing thoroughly. Treatment duration may vary but is generally several weeks to months[3].

7.4 Treatment Considerations in Special Populations

Tinea capitis can present unique challenges in certain populations, including pediatric patients, immunocompromised individuals, and pregnant or lactating women. Treatment strategies must be carefully tailored to address the specific needs and considerations of these special populations, ensuring optimal efficacy while minimizing potential risks[43].

Here are important treatment considerations for tinea capitis in special populations is given below in Table 3.

Table 3: Treatment Considerations for Tinea Capitis in Special Population

Treatment Considerations	Pediatric Patients	Immunocompromised Individuals	Elderly Patients	Pregnant OR Lactating Women
Special Considerations[6]	Tinea capitis is most commonly observed in pediatric populations, particularly school-aged children. Children may present with a variety of clinical manifestations, including inflammatory kerion or non-inflammatory types, which may influence treatment decisions.	Immunocompromised individuals, including those with human immunodeficiency virus (HIV) infection, organ transplant recipients, or individuals receiving immunosuppressive therapy, may be at increased risk of developing tinea capitis. Tinea capitis in immunocompromised individuals may present with atypical clinical features or more severe disease, requiring aggressive treatment approaches.	Elderly patients may present with tinea capitis due to age-related changes in immune function, underlying medical conditions, or institutional living arrangements. Comorbidities such as diabetes mellitus, peripheral vascular disease, or neurologic	Pregnancy and lactation pose unique considerations in the management of tinea capitis, as treatment options must balance efficacy with maternal and fetal safety. Topical antifungal agents may be preferred in pregnant or lactating women to minimize systemic absorption and potential fetal exposure.
Treatment Recommendations2	Systemic antifungal therapy is often necessary for the treatment of tinea capitis in children, as topical agents may be less effective due to limited scalp penetration and compliance issues. Griseofulvin is the preferred systemic antifungal agent for tinea capitis in children due to its long-standing safety profile and efficacy, especially in infections caused by Microsporum species. Treatment duration with griseofulvin typically ranges from 6 to 12 weeks, with close monitoring for adverse effects such as gastrointestinal upset and photosensitivity.	Systemic antifungal therapy is typically recommended for the treatment of tinea capitis in immunocompromised individuals, given the potential for widespread or refractory disease. Azole antifungal agents such as itraconazole or fluconazole may be preferred in immunocompromised patients due to their broader spectrum of activity and favorable safety profile. Close monitoring for drug interactions and potential hepatotoxicity is essential when using systemic azole antifungal agents in immunocompromised individuals, particularly those receiving concomitant medications or with underlying liver disease.	Treatment of tinea capitis in elderly patients should consider the individual's overall health status, comorbidities, and medication regimen. Systemic antifungal therapy may be preferred in elderly patients with extensive or severe disease, with consideration of drug interactions and potential adverse effects. Topical antifungal agents may be suitable for mild cases of tinea capitis in elderly patients or as adjunctive therapy to systemic agents.	Topical antifungal agents such as ketoconazole or ciclopirox may be used as first-line therapy for tinea capitis in pregnant or lactating women, with systemic agents reserved for refractory cases or severe disease. Treatment duration with topical antifungal agents may need to be extended in pregnant or lactating women to ensure eradication of the fungal infection. Close monitoring for adverse effects, such as skin irritation or allergic reactions, is important when using topical antifungal agents during pregnancy or lactation.

8. FUTURE DIRECTIONS AND EMERGING TRENDS

The emergence of drug-resistant strains and the limitations of conventional antifungal therapies have spurred research into novel therapeutic approaches for tinea capitis. These innovative strategies aim to enhance treatment efficacy while addressing challenges such as prolonged treatment duration, potential adverse effects, and recurrence of infection[44]. Nanotechnology-based antifungals hold promise by improving drug delivery through enhanced solubility, stability, and bioavailability[45]. Nanoparticle formulations of existing antifungal drugs, such as griseofulvin or azoles, have demonstrated efficacy in preclinical studies by improving drug penetration into hair follicles and achieving sustained release at the infection site. Photodynamic therapy (PDT) offers another potential adjunctive therapy by inducing localized phototoxicity and fungal cell destruction, particularly effective against Trichophyton species[46]. Natural products and herbal therapies present alternative treatment options with potential antifungal activity and fewer adverse effects compared to synthetic drugs. Plant-derived compounds like tea tree oil and neem oil have shown promising antifungal properties against dermatophyte fungi implicated in tinea capitis[47]. Host-targeted therapies, such as immunomodulatory agents, aim to enhance the host immune response against fungal infections and reduce associated inflammation. Novel antifungal agents, including cyclic peptides and squalene synthase inhibitors, are being developed to overcome resistance mechanisms and improve treatment outcomes. Additionally, microbiome-based therapies are under investigation to restore microbial balance and enhance the skin's natural defense mechanisms against fungal infections. These novel therapeutic approaches offer new avenues for combating tinea capitis and improving treatment outcomes. Further clinical studies are needed to evaluate their safety, efficacy, and feasibility for eventual incorporation into standard treatment regimens[48].

9. CONCLUSION

In conclusion, tinea capitis remains a significant public health concern, particularly in pediatric populations, due to its contagious nature, potential for outbreaks, and impact on affected individuals and communities. While conventional antifungal therapies have been the mainstay of treatment, the emergence of drug-resistant strains and limitations of current treatments have prompted research into novel therapeutic approaches. From nanotechnology-based drug delivery systems to host-targeted immunomodulatory therapies and microbiome-based interventions, ongoing research efforts are expanding the treatment armamentarium for tinea capitis and offering new avenues for combating this common fungal infection. Despite these advancements, several research needs and opportunities persist in the field of tinea capitis. Addressing these gaps in knowledge, such as drug resistance mechanisms, optimization of treatment regimens, development of novel therapeutics, and elucidation of host-pathogen interactions, can lead to innovative solutions and improvements in disease management, prevention, and outcomes. Additionally, further research into diagnostic tools, epidemiology, transmission dynamics, public health interventions, and long-term outcomes of tinea capitis treatment is essential to inform evidence-based practices and strategies for controlling the spread of the infection. Collaboration among researchers, healthcare providers, public health authorities, and community stakeholders is crucial to drive progress in tinea capitis research and translate findings into clinical practice. By working together, we can

continue to advance our understanding of tinea capitis and develop effective strategies to reduce the burden of this common fungal infection, ultimately improving the health and well-being of individuals at risk.

Consent For Publication

Not applicable.

Funding

This work did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

Refrences

1) Gupta AK, Foley KA, Versteeg SG. Tinea capitis: An overview with emphasis on management. Pediatr Dermatol. 2019;36(5):634-645.

2) Elewski BE. Tinea capitis: A current perspective. J Am Acad Dermatol. 2000;42(1 Pt 1):1-20.

3) Hay RJ. Tinea capitis: Current status. Mycopathologia. 2017;182(1-2):87-93.

4) Tey HL, Tan AS, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol. 2011;64(4):663-670.

5) Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51 Suppl 4:2-15.

6) Verrier J, Monod M. Diagnosis of dermatophytosis using molecular biology. Mycopathologia. 2017;182(1-2):193-202.

7) Gupta AK, Chaudhry M, Elewski B. Tinea capitis. Dermatol Clin. 2003;21(2):247-256.

8) Fuller LC, Child FC, Higgins EM, Du Vivier AW. A double-blind, randomized, placebo-controlled trial of griseofulvin and terbinafine in the treatment of tinea capitis. Br J Dermatol. 1997;136(4):575-577.

9) Aly R, Berger TG. Common superficial fungal infections in patients with human immunodeficiency virus infection. J Am Acad Dermatol. 1996;34(5 Pt 1):835-846.

10) Elewski BE. Tinea capitis. Semin Cutan Med Surg. 1996;15(3):236-241.

11) Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732-1744.

12) Loo DS, Lee A. Tinea capitis update: a continuing conflict with an old adversary. Curr Opin Pediatr. 2011;23(4):436-441.

13) Shemer A, Trau H, Davidovici B, Amichai B, Grunwald MH. Tinea capitis outbreak in a dermatology office. Int J Dermatol. 2004;43(4):288-291.

14) El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014;(8):CD009992.

15) Hay RJ. Advances in skin and wound care in the last 30 years: dermatophyte infections. Ostomy Wound Manage. 2017;63(11):10-12.

16) Arenas R. Tinea capitis: A current perspective. Ther Adv Infect Dis. 2019;6:2049936119837701.

17) Bouziane F, Boutimzine N, Charoute H, et al. Aetiological agents of tinea capitis in children attending the Dermatology Department of the University Hospital of Fez, Morocco: a 5-year retrospective study (2010-2014). J Mycol Med. 2018;28(1):93-96.

18) Emmons CW. Isolation of the asexual state of the agents of the North American scalp ringworm. J Invest Dermatol. 1949;12(5):283-293.

19) Svejgaard EL, Nilsson J, Johansen JD, Andersen KE, Thormann J. Tinea capitis in Denmark, 1992 to 2002: a 10-year survey of the current incidence, clinical patterns, and treatment regimens. Acta Derm Venereol. 2006;86(6):509-512.

20) Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population - a literature study. J Eur Acad Dermatol Venereol. 2014;28(11):1480-1491

21) Abdel-Rahman SM, Preuett B, Williams JM, et al. Pharmacokinetics of griseofulvin ultramicrosize tablets in children. J Pediatr. 2005;146(6):812-816.

22) Arenas R. Tinea capitis: A current perspective. Ther Adv Infect Dis. 2019;6:2049936119837701.

23) Bouziane F, Boutimzine N, Charoute H, et al. Aetiological agents of tinea capitis in children attending the Dermatology Department of the University Hospital of Fez, Morocco: a 5-year retrospective study (2010-2014). J Mycol Med. 2018;28(1):93-96.

24) Elewski BE. Tinea capitis: A current perspective. J Am Acad Dermatol. 2000;42(1 Pt 1):1-20.

25) El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014;(8):CD009992.

26) Emmons CW. Isolation of the asexual state of the agents of the North American scalp ringworm. J Invest Dermatol. 1949;12(5):283-293.

27) Fuller LC, Child FC, Higgins EM, Du Vivier AW. A double-blind, randomized, placebo-controlled trial of griseofulvin and terbinafine in the treatment of tinea capitis. Br J Dermatol. 1997;136(4):575-577.

28) Gupta AK, Chaudhry M, Elewski B. Tinea capitis. Dermatol Clin. 2003;21(2):247-256.

29) Gupta AK, Foley KA, Versteeg SG. Tinea capitis: An overview with emphasis on management. Pediatr Dermatol. 2019;36(5):634-645.

30) Hay RJ. Advances in skin and wound care in the last 30 years: dermatophyte infections. Ostomy Wound Manage. 2017;63(11):10-12.

31) Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51 Suppl 4:2-15.

32) Loo DS, Lee A. Tinea capitis update: a continuing conflict with an old adversary. Curr Opin Pediatr. 2011;23(4):436-441.

33) Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732-1744.

34) Shemer A, Trau H, Davidovici B, Amichai B, Grunwald MH. Tinea capitis outbreak in a dermatology office. Int J Dermatol. 2004;43(4):288-291.

35) Svejgaard EL, Nilsson J, Johansen JD, Andersen KE, Thormann J. Tinea capitis in Denmark, 1992 to 2002: a 10-year survey of the current incidence, clinical patterns, and treatment regimens. Acta Derm Venereol. 2006;86(6):509-512.

36) Tey HL, Tan AS, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol. 2011;64(4):663-670.

37) Verrier J, Monod M. Diagnosis of dermatophytosis using molecular biology. Mycopathologia. 2017;182(1-2):193-202.

38) Aly R, Berger TG. Common superficial fungal infections in patients with human immunodeficiency virus infection. J Am Acad Dermatol. 1996;34(5 Pt 1):835-846.

39) Elewski BE. Tinea capitis. Semin Cutan Med Surg. 1996;15(3):236-241.

40) Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population - a literature study. J Eur Acad Dermatol Venereol. 2014;28(11):1480-1491.

41) Elewski BE. Tinea capitis: A current perspective. J Am Acad Dermatol. 2000;42(1 Pt 1):1-20.

42) Fuller LC, Child FC, Higgins EM, Du Vivier AW. A double-blind, randomized, placebo-controlled trial of griseofulvin and terbinafine in the treatment of tinea capitis. Br J Dermatol. 1997;136(4):575-577.

43) Gupta AK, Chaudhry M, Elewski B. Tinea capitis. Dermatol Clin. 2003;21(2):247-256.

44) Hay RJ. Advances in skin and wound care in the last 30 years: dermatophyte infections. Ostomy Wound Manage. 2017;63(11):10-12.

45) Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51 Suppl 4:2-15.

46) Loo DS, Lee A. Tinea capitis update: a continuing conflict with an old adversary. Curr Opin Pediatr. 2011;23(4):436-441.

47) Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population - a literature study. J Eur Acad Dermatol Venereol. 2014;28(11):1480-1491.

48) Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732-1744.